News

Deal Announcements

BioVex Lands $30 Million Series F Venture Funding

Thursday, November 12, 2009 5:32:00 AM PDT | VentureDeal Staff
Woburn, Massachusetts  --  Biotechnology company BioVex has secured $30 million in its sixth round of institutional venture capital investment.

BioVex says it is developing a "new class of potent biologics for the treatment of cancer and prevention of infectious disease."

Investors in the round included Morningside Group, Ventech, MVM Life Science Partners and other undisclosed investors.  The company said that the funding proceeds would be used to complete its Phase III melanoma drug treatment candidate.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1